The structural and functional impacts of rationally designed cyclic peptides on self-assembly-mediated functionality

Taichi Kurita and Keiji Numata

Phys. Chem. Chem. Phys., 2024, 26, 28776
DOI: 10.1039/D4CP02759K

A systematic molecular dynamics approach to the study of peptide Keap1–Nrf2 protein–protein interaction inhibitors and its application to p62 peptides

Meng-Chen Lu, Zhen-Wei Yuan, Yong-Lin Jiang, Zhi-Yun Chen, Qi-Dong You and Zheng-Yu Jiang

Mol. BioSyst., 2016, 12, 1378
DOI: 10.1039/C6MB00030D

A cell-active cyclic peptide targeting the Nrf2/Keap1 protein–protein interaction

Jessica Iegre, Sona Krajcovicova, Anders Gunnarsson, Lisa Wissler, Helena Käck, Anna Luchniak, Stefan Tångefjord, Frank Narjes and David R. Spring

Chem. Sci., 2023, 14, 10800
DOI: 10.1039/D3SC04083F

Advances in targeted degradation of endogenous proteins

Sascha Röth, Luke J. Fulcher and Gopal P. Sapkota

Cell. Mol. Life Sci., 2019, 76, 2761
DOI: 10.1007/s00018-019-03112-6

Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors

Yi Mou, Shuai Wen, Yu-Xiu Li, Xin-Xing Gao, Xin Zhang and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2020, 202, 112532
DOI: 10.1016/j.ejmech.2020.112532

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

Hai-Shan Zhou, Lv-Bin Hu, Han Zhang, Wen-Xin Shan, Yan Wang, Xue Li, Tian Liu, Jing Zhao, Qi-Dong You and Zheng-Yu Jiang

J. Med. Chem., 2020, 63, 11149
DOI: 10.1021/acs.jmedchem.0c01116

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope

Sinan Ma, Jianai Ji, Yuanyuan Tong, Yuxuan Zhu, Junwei Dou, Xian Zhang, Shicheng Xu, Tianbao Zhu, Xiaoli Xu, Qidong You and Zhengyu Jiang

Acta Pharmaceutica Sinica B, 2022, 12, 2990
DOI: 10.1016/j.apsb.2022.02.022

Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress

Jing Chen, Disheng Feng, Rui Zhu, Hua Li and Lixia Chen

Redox Biology, 2025, 85, 103781
DOI: 10.1016/j.redox.2025.103781

Exploring new strategies for grafting binding peptides onto protein loops using a consensus‐designed tetratricopeptide repeat scaffold

Sarah K. Madden, Albert Perez‐Riba and Laura S. Itzhaki

Protein Science, 2019, 28, 738
DOI: 10.1002/pro.3586

Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1–Nrf2) Protein–Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity

Meng-Chen Lu, Xian Zhang, Feng Wu, Shi-Jie Tan, Jing Zhao, Qi-Dong You and Zheng-Yu Jiang

J. Med. Chem., 2019, 62, 6796
DOI: 10.1021/acs.jmedchem.9b00818

Discovery of 2-oxy-2-phenylacetic acid substituted naphthalene sulfonamide derivatives as potent KEAP1-NRF2 protein-protein interaction inhibitors for inflammatory conditions

Meng-Chen Lu, Hong-Li Shao, Tian Liu, Qi-Dong You and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2020, 207, 112734
DOI: 10.1016/j.ejmech.2020.112734

Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics

Lisha Ou, Mekedlawit T. Setegne, Jeandele Elliot, Fangfang Shen and Laura M. K. Dassama

Chem. Rev., 2025, 125, 2120
DOI: 10.1021/acs.chemrev.4c00595

Polar Recognition Group Study of Keap1-Nrf2 Protein–Protein Interaction Inhibitors

Meng-Chen Lu, Shi-Jie Tan, Jian-Ai Ji, Zhi-Yun Chen, Zhen-Wei Yuan, Qi-Dong You and Zheng-Yu Jiang

ACS Med. Chem. Lett., 2016, 7, 835
DOI: 10.1021/acsmedchemlett.5b00407

PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders

Shusuke Tomoshige and Minoru Ishikawa

Angew Chem Int Ed, 2021, 60, 3346
DOI: 10.1002/anie.202004746

Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interaction

Richard J. Steel, Maria A. O'Connell and Mark Searcey

Bioorganic & Medicinal Chemistry Letters, 2018, 28, 2728
DOI: 10.1016/j.bmcl.2018.03.003

Nrf2 activation through the inhibition of Keap1–Nrf2 protein–protein interaction

Sumi Lee and Longqin Hu

Med Chem Res, 2020, 29, 846
DOI: 10.1007/s00044-020-02539-y

The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update

Meng‐Chen Lu, Jian‐Ai Ji, Zheng‐Yu Jiang and Qi‐Dong You

Medicinal Research Reviews, 2016, 36, 924
DOI: 10.1002/med.21396

Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides

Mikko Karttunen, Wing-Yiu Choy and Elio A. Cino

J. Phys. Chem. B, 2018, 122, 5851
DOI: 10.1021/acs.jpcb.8b03295

Computational Prediction of Cyclic Peptide Structural Ensembles and Application to the Design of Keap1 Binders

Francini Fonseca Lopez, Jiayuan Miao, Jovan Damjanovic, Luca Bischof, Michael B. Braun, Yingjie Ling, Marcus D. Hartmann, Yu-Shan Lin and Joshua A. Kritzer

J. Chem. Inf. Model., 2023, 63, 6925
DOI: 10.1021/acs.jcim.3c01337

Screening approaches for the identification of Nrf2-Keap1 protein-protein interaction inhibitors targeting hot spot residues

Wataru Asano, Rie Hantani, Toru Uhara, François Debaene, Akihiro Nomura, Keishi Yamaguchi, Tsuyoshi Adachi, Kazuki Otake, Kazuhito Harada and Yoshiji Hantani

SLAS Discovery, 2024, 29, 100125
DOI: 10.1016/j.slasd.2023.11.001

Baicalein disrupts the KEAP1-NRF2 interaction to alleviate oxidative stress injury by inhibiting M1 macrophage polarization

Fuyun Chi, Chuanjing Cheng, Kaixin Liu, Tong Sun, Man Zhang, Yuanyuan Hou and Gang Bai

Free Radical Biology and Medicine, 2025, 227, 557
DOI: 10.1016/j.freeradbiomed.2024.12.036

Structure-activity relationships of 1,4-bis(arylsulfonamido)-benzene or naphthalene-N,N′-diacetic acids with varying C2-substituents as inhibitors of Keap1-Nrf2 protein-protein interaction

Sumi Lee, Dhulfiqar Ali Abed, Mai-Uyen Nguyen, Michael P. Verzi and Longqin Hu

European Journal of Medicinal Chemistry, 2022, 237, 114380
DOI: 10.1016/j.ejmech.2022.114380

Design, synthesis and evaluation of -amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1

Zhiyan Li, Zhenguo Zhang, Yanhong Chen, Shijun Tang, Tongyuan Lin, Jingfang Huang, Bo Li and Cheng Jiang

Bioorganic Chemistry, 2019, 85, 534
DOI: 10.1016/j.bioorg.2019.02.022

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)

Huifang Wang, Runhua Zhou, Fushan Xu, Kongjun Yang, Liuhai Zheng, Pan Zhao, Guangwei Shi, Lingyun Dai, Chengchao Xu, Le Yu, Zhijie Li, Jianhong Wang and Jigang Wang

Biomater Res, 2023, 27
DOI: 10.1186/s40824-023-00385-8

Design, synthesis and biological evaluation of phosphopeptides as Polo-like kinase 1 Polo-box domain inhibitors

Tong-yuan Lin, Hong-ping Min, Cheng Jiang, Miao-miao Niu, Fang Yan, Li-li Xu and Bin Di

Bioorganic & Medicinal Chemistry, 2018, 26, 3429
DOI: 10.1016/j.bmc.2018.05.014

Design, Synthesis, and Initial Evaluation of Affinity-Based Small-Molecule Probes for Fluorescent Visualization and Specific Detection of Keap1

Mengchen Lu, Hai-shan Zhou, Qi-Dong You and Zhengyu Jiang

J. Med. Chem., 2016, 59, 7305
DOI: 10.1021/acs.jmedchem.6b00775

Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: A new strategy to improve therapeutic peptide activity against sepsis

Ke Chen, Liuliu Huang and Bin Shen

Biophysical Chemistry, 2019, 244, 22
DOI: 10.1016/j.bpc.2018.11.002

Direct Keap1-kelch inhibitors as potential drug candidates for oxidative stress-orchestrated diseases: A review on In silico perspective

Ibrahim Damilare Boyenle, Ukachi Chiamaka Divine, Rofiat Adeyemi, Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba, Chowdhry Apu, Lei Du, Qian Lu, Xiaoxing Yin and Temitope Isaac Adelusi

Pharmacological Research, 2021, 167, 105577
DOI: 10.1016/j.phrs.2021.105577

Discovery of a head-to-tail cyclic peptide as the Keap1-Nrf2 protein-protein interaction inhibitor with high cell potency

Meng-Chen Lu, Qiong Jiao, Tian Liu, Shi-Jie Tan, Hai-Shan Zhou, Qi-Dong You and Zheng-Yu Jiang

European Journal of Medicinal Chemistry, 2018, 143, 1578
DOI: 10.1016/j.ejmech.2017.10.052

Development of Keap1-interactive small molecules that regulate Nrf2 transcriptional activity

Nikolaos D. Georgakopoulos, Jemma Gatliff and Geoff Wells

Current Opinion in Toxicology, 2016, 1, 1
DOI: 10.1016/j.cotox.2016.08.002

Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1

Yanhong Chen, Zhiyan Li, Yu Liu, Tongyuan Lin, Huiyong Sun, Dasong Yang and Cheng Jiang

Bioorganic Chemistry, 2018, 81, 278
DOI: 10.1016/j.bioorg.2018.08.030

Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics

Colin S. Swenson, Gunasheil Mandava, Deborah M. Thomas and Raymond E. Moellering

Chem. Rev., 2024, 124, 13020
DOI: 10.1021/acs.chemrev.4c00423

Development of p62-Keap1 protein–protein interaction inhibitors as doxorubicin-sensitizers against non-small cell lung cancer

Daisuke Yasuda, Ippei Yoshida, Riyo Imamura, Daiki Katagishi, Kyoko Takahashi, Hirotatsu Kojima, Takayoshi Okabe, Yoshinobu Ichimura, Masaaki Komatsu, Tadahiko Mashino and Tomoyuki Ohe

Results in Chemistry, 2022, 4, 100609
DOI: 10.1016/j.rechem.2022.100609

Cyclic Peptide Keap1–Nrf2 Protein–Protein Interaction Inhibitors: Design, Synthesis, and In Vivo Treatment of Acute Lung Injury

Jihua Zou, Jianyu Yan, Yifei Lu, Zhou Yu, Kai Zhang, Qianyu Han, Dan Han, Conghao Gai, Xiaoyun Chai, Qingjie Zhao, Chunlin Zhuang and Yan Zou

J. Med. Chem., 2024, 67, 4889
DOI: 10.1021/acs.jmedchem.4c00065

Exploring the binding of rationally engineered tandem-repeat proteins to E3 ubiquitin ligase Keap1

Sarah K Madden, Laura S Itzhaki and Skerra Arne

Protein Engineering, Design and Selection, 2021, 34
DOI: 10.1093/protein/gzab027

Computational design of diverse nuclear factor erythroid 2 activators with cellular antioxidative activity

Mingyue Yuwen, Xiaoning Gao, Junli Ba, Jiayang Wu, Jun Kang, Sheng Ye and Cheng Zhu

iScience, 2025, 28, 112621
DOI: 10.1016/j.isci.2025.112621

Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning

Paula C. Ortet, Samantha N. Muellers, Lauren A. Viarengo-Baker, Kristina Streu, Blair R. Szymczyna, Aaron B. Beeler, Karen N. Allen and Adrian Whitty

J. Am. Chem. Soc., 2021, 143, 3779
DOI: 10.1021/jacs.0c09799

Nrf2/Keap1/ARE signaling: Towards specific regulation

Alexey V. Ulasov, Andrey A. Rosenkranz, Georgii P. Georgiev and Alexander S. Sobolev

Life Sciences, 2022, 291, 120111
DOI: 10.1016/j.lfs.2021.120111

Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein–Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions

Zheng-Yu Jiang, Meng-Chen Lu and Qi-Dong You

J. Med. Chem., 2016, 59, 10837
DOI: 10.1021/acs.jmedchem.6b00586

Interfering peptides targeting protein–protein interactions: the next generation of drugs?

Heriberto Bruzzoni-Giovanelli, Valerie Alezra, Nicolas Wolff, Chang-Zhi Dong, Pierre Tuffery and Angelita Rebollo

Drug Discovery Today, 2018, 23, 272
DOI: 10.1016/j.drudis.2017.10.016

Inhibiting the Keap1/Nrf2 Protein‐Protein Interaction with Protein‐Like Polymers

Kendal P. Carrow, Haylee L. Hamilton, Madeline P. Hopps, Yang Li, Baofu Qiao, N. Connor Payne, Matthew P. Thompson, Xiaoyu Zhang, Assa Magassa, Mara Fattah, Shivangi Agarwal, Michael P. Vincent, Marina Buyanova, Paul A. Bertin, Ralph Mazitschek, Monica Olvera de la Cruz, Delinda A. Johnson, Jeffrey A. Johnson and Nathan C. Gianneschi

Advanced Materials, 2024, 36
DOI: 10.1002/adma.202311467

Li-Li Xu, Xian Zhang, Zheng-Yu Jiang and Qi-Dong You

Bioorganic & Medicinal Chemistry, 2016, 24, 3540
DOI: 10.1016/j.bmc.2016.05.056

KEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

Enrique Crisman, Pablo Duarte, Esteban Dauden, Antonio Cuadrado, María Isabel Rodríguez‐Franco, Manuela G. López and Rafael León

Medicinal Research Reviews, 2023, 43, 237
DOI: 10.1002/med.21925

The emerging role of proteolysis targeting chimeras (PROTACs) in the treatment of Alzheimer’s disease

Namy George, Md. Jawaid Akhtar, Khalid Al Balushi, Sher Zaman Safi, Syed Najmul Hejaz Azmi and Shah Alam Khan

Med Chem Res, 2023
DOI: 10.1007/s00044-023-03026-w

Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway

Mengchen Lu, Tian Liu, Qiong Jiao, Jianai Ji, Mengmin Tao, Yijun Liu, Qidong You and Zhengyu Jiang

European Journal of Medicinal Chemistry, 2018, 146, 251
DOI: 10.1016/j.ejmech.2018.01.063

Modified Peptide Inhibitors of the Keap1–Nrf2 Protein–Protein Interaction Incorporating Unnatural Amino Acids

Nikolaos D. Georgakopoulos, Sandeep K. Talapatra, Jemma Gatliff, Frank Kozielski and Geoff Wells

ChemBioChem, 2018, 19, 1810
DOI: 10.1002/cbic.201800170

PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders

Shusuke Tomoshige and Minoru Ishikawa

Angewandte Chemie, 2021, 133, 3386
DOI: 10.1002/ange.202004746